Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative FOLFIRINOX for Resectable Pancreatic Adenocarcinoma
NCT02345460Phase 2Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Sep 2015
- Primary completion
- Feb 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, folinic acid and fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by Case Comprehensive Cancer Center. Started Sep 2015; status: terminated.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatinfolinic acidfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02345460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345460.